API & SDK Solutions
Data integration solutions for OEMs and partners
Api · Api OnlyCompany source
Company profile
About AliveCor
AliveCor is a digital health company pioneering accessible cardiac care through AI-enabled ECG technology. Founded on proprietary machine learning-powered ECG sensors, AliveCor delivers medical-grade heart data anytime, anywhere. The company's flagship Kardia product line includes KardiaMobile personal ECG devices for consumers, KardiaMobile 6L for clinical and research use, and Kardia 12L—the first portable 12-lead ECG system lighter than a smartphone. AliveCor's technology has recorded over 300 million ECGs worldwide and is backed by more than 200 clinical publications. The company serves multiple market segments: consumers seeking remote cardiac monitoring, healthcare professionals requiring real-time heart rhythm analysis, biopharma partners conducting clinical trials and safety monitoring, health systems implementing enterprise remote patient monitoring platforms, and payers and employers managing cardiac health costs. AliveCor's AI algorithms are FDA-cleared to detect up to 39 cardiac determinations including atrial fibrillation, bradycardia, tachycardia, myocardial infarction, and ischemia. The company's software ecosystem includes KardiaPro for clinical workflow integration, KardiaStation for point-of-care use, and KardiaComplete for comprehensive cardiac care management. With over 5 million lifetime users across 40+ countries, AliveCor is advancing its mission to transform cardiovascular care by improving diagnosis, treatment, and reducing disparities in cardiac care access.
Company description AliveCor official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at AliveCor?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Arrhythmias
- Atrial Enlargement
- Atrial Fibrillation
- Atrial Flutter
- Bradycardia
- Bundle Branch Blocks (RBBB, LBBB)
- Cardiac Ischemia
- Heart Block
- Myocardial Infarction (Anterior, Inferior, Lateral)
- Premature Ventricular Contractions (PVCs)
- Prolonged QT
- Supraventricular Ectopy (SVE)
- Tachycardia
- Ventricular Hypertrophy
- Wolff-Parkinson-White Syndrome
Who it serves
- Biopharma Companies
- Cardiologists
- Clinical Research Organizations
- Consumers/Patients
- Employers
- Health Systems
- Healthcare Providers
- OEM Partners
- Payers
- Veterans Affairs
Deployment & integration
Api Only · Cloud Saas · Hybrid deployment with recorded integration context.
Geographic context
Markets40+ countries internationally · United States
Company sourceOfficial website
Company milestones
Platform expansion
Launch of Kardia 12L as first-of-its-kind portable 12-lead ECG system. Two-week trial program for eligible U.S. healthcare professionals. Presentation of Kardia 12L clinical study data at Heart Rhythm Society 2024. Launch of K1000 with InstantQT technology.
Partnerships
Recorded partners
- Fortune 100 employers
- Large CROs
- Leading U.S. medical institutions (for AI training data)
- Major healthcare systems
- Top biopharma companies
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
K1000 (InstantQT)
Medical-grade ECGs with InstantQT in 30 seconds for cardiac monitoring
Device · HybridCompany source
Kardia 12L
First-of-its-kind portable 12-lead ECG lighter than a smartphone
Device · HybridCompany source
KardiaCare Plus
Enhanced cardiac care subscription service
Service · Cloud SaaSCompany source
KardiaComplete
End-to-end cardiac care solution for remote patient monitoring
Service · Cloud SaaSCompany source
KardiaMobile
Original FDA-cleared single-lead personal EKG recording on your phone
Device · Cloud SaaSCompany source
KardiaMobile 6L
First FDA-cleared 6-lead personal ECG device capturing medical-grade ECG in 30 seconds
Device · HybridCompany source
KardiaMobile Card
First personal EKG the size of a standard credit card
Device · Cloud SaaSCompany source
KardiaPro
Secure web portal for managing and reviewing patient ECG history
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Wellens' Sign and Syndrome Detected With the Home Use of a Novel 12-Lead Electrocardiogram.JACC. Case reports · Jul 29, 2026
The Harvard-Emory ECG Database.Scientific data · Feb 25, 2026
Toward self-validating ECG Systems: A personalized, uncertainty-aware approach for detecting and estimating lead misplacement.Journal of electrocardiology · Jan 1, 2026
Estimating blood pressure from the electrocardiogram: findings of a large-scale negative results study.Physiological measurement · Nov 10, 2025
Cardiovascular Sciences Research Consortium Think Tank: Remote Monitoring for Cardiac Safety in Clinical Trials.JACC. Advances · Sep 1, 2025
The Harvard-Emory ECG Database.medRxiv : the preprint server for health sciences · May 9, 2025
Clinical validation
Clinical-trial records
Acute Responses to Exercise in Females and Males With Symptomatic Atrial FibrillationNCT05085860 · Mentioned · COMPLETED
A Deep Learning Method to Evaluate QT on RibociclibNCT05623397 · Mentioned · COMPLETED
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction IINCT06271577 · Sponsor · RECRUITING
Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol PatientsNCT02241252 · Mentioned · COMPLETED
Screening for Atrial Fibrillation in Patients With Cancer: A Pilot Randomized Controlled Clinical TrialNCT05784766 · Mentioned · ACTIVE NOT RECRUITING
A Behavioural Weight Loss Intervention Delivered in Cardiac Rehabilitation for Patients With Atrial Fibrillation and ObesityNCT05600829 · Mentioned · ACTIVE NOT RECRUITING
Regulatory
Regulatory records
Corvair MonzaK252589 · 510k · Jan 9, 2026
ImpalaK232035 · 510k · Jun 7, 2024
CorvairK231010 · 510k · Jun 7, 2024
AliveCor QT ServiceK212662 · 510k · Apr 26, 2022
KardiaAIK201985 · 510k · Nov 12, 2020
KardiaAIK181823 · 510k · Mar 11, 2019
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
300M+ ECGs recorded worldwide
Total ECG recordings across all AliveCor devices globally
5M+ lifetime users
Users across 40+ countries
4,000+ instances of MI and ischemia detected
Detected across 27,000+ patients in 250+ practices using Kardia 12L
Heart Rhythm Society 2024 Study
Clinical validation study comparing Kardia 12L diagnostic accuracy to standard 12-lead ECG
200 patients studied showing rapid acquisition of resting ECG information with significant implications for rapid ECG diagnosis in clinical practice
Kardia 12L Early Adopters
Deployment of portable 12-lead ECG across multiple practices for improved cardiac diagnosis
27,000+ patients served across 250+ practices with 4,000+ instances of myocardial infarction and ischemia detected
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from AliveCor
Recent articles published on AliveCor's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.